A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

Clinical trial NCT07038460 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07038460
Sponsor: Wen-zhao ZHONG
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Non-small Cell Lung Cancer

Start date: 2025-07-01
Primary completion: 2027-12-01
Enrollment: 134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.